6678.T(6678.T)

$2045.00—Stale · unknown old

WatchlistAsk SA Chart

6678.T(6678.T)

JPX • Last print unknown ago

$2045.00—Stale · unknown old

WatchlistAsk SA Chart Studio

6678.T(6678.T)

6678.T

9/25/26

Techno Medica (6678.T)

Friday

6:02 AM

ThesisPositive clinical trial results and strategic partnerships are enhancing growth prospects, leading to a more favorable outlook among investors.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$9.9B	$11.2B
Rev. Growth	-3.7%	+13.4%
EPS	$145.08	$155.28
EPS Growth	-16.1%	+7.0%
P/E	14.1×	13.2×

What’s Driving the Stock

01Recent clinical trial results show a 25% improvement in diagnostic accuracy for new imaging technology, potentially increasing market share.
02Expansion into Southeast Asia with a new distribution partnership expected to increase revenue by 15% over the next year.
03Cost reductions achieved through manufacturing efficiencies could boost operating margins by 200 basis points.
04Digital health integration
05AI in medical diagnostics
06Regulatory approvals for new medical devices
07Market penetration in emerging Asian markets
08Technological advancements in imaging and therapeutic solutions

FY2025 Snapshot

Revenue: $11.2B
Rev. Growth: +13.4%
Gross Margin: 46.7%
Op. Margin: 14.8%
Net Margin: 9.5%
Net Income: $1.1B
NI Growth: +6.6%
EPS: $155.28
1Y Return: -0.6%

6678.T Chart

My Notes

"The advancements in our imaging technology position us strongly for market leadership."
Moat: Techno Medica's proprietary technologies and established relationships in the healthcare sector provide a durable competitive advantage.
growth - Investors are likely attracted to the company's potential for innovation and expansion in emerging markets.
Interest rates affect the company's cost of capital for R&D investments and may influence healthcare spending; however…
Watch on earnings: Regulatory approval timelines for new devices, Market share in Asia-Pacific regions, Gross margin trends.

One Sentence Summary:

Techno Medica: the setup is constructive — recent clinical trial results show a 25% improvement in diagnostic accuracy for new imaging technology, potentially increasing market share.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2024

FY2025

P/E

14.1×

13.2×

What’s Driving the Stock

01Recent clinical trial results show a 25% improvement in diagnostic accuracy for new imaging technology, potentially increasing market share.

02Expansion into Southeast Asia with a new distribution partnership expected to increase revenue by 15% over the next year.

03Cost reductions achieved through manufacturing efficiencies could boost operating margins by 200 basis points.

04Digital health integration

05AI in medical diagnostics

06Regulatory approvals for new medical devices

07Market penetration in emerging Asian markets

08Technological advancements in imaging and therapeutic solutions

My Notes

"The advancements in our imaging technology position us strongly for market leadership."

Moat: Techno Medica's proprietary technologies and established relationships in the healthcare sector provide a durable competitive advantage.

growth - Investors are likely attracted to the company's potential for innovation and expansion in emerging markets.

Interest rates affect the company's cost of capital for R&D investments and may influence healthcare spending; however…

Watch on earnings: Regulatory approval timelines for new devices, Market share in Asia-Pacific regions, Gross margin trends.